Trials / Conditions / Neurotrophic Keratitis

Neurotrophic Keratitis

25 registered clinical trials studyying Neurotrophic Keratitis — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Corneal Neurotization vs. Cenergermin for Neurotrophic Keratitis: A Pilot Study NCT07073729	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	N/A
Recruiting	A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis NCT06999733	Krystal Biotech, Inc.	Phase 1 / Phase 2
Recruiting	A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis NCT06975748	Staidson (Beijing) Biopharmaceuticals Co., Ltd	Phase 2
Recruiting	Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Au NCT06964269	Toyos Clinic	Phase 4
Completed	A Study of STSP-0902 Ophthalmic Solution in Healthy Subjects NCT06597422	Staidson (Beijing) Biopharmaceuticals Co., Ltd	Phase 1
Recruiting	Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Ker NCT05927428	BRIM Biotechnology Inc.	Phase 2
Terminated	Differences in Corneal Structure and Function in Patients With Sjogrens vs. Non-Sjogrens Dry Eye NCT06364657	Johns Hopkins University	—
Withdrawn	Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Kera NCT06411145	Dompé Farmaceutici S.p.A	Phase 4
Suspended	QST for Corneal Nerve Function NCT05758753	Tufts Medical Center	N/A
Completed	DEFENDO Long Term Follow-up Study in Stage 1 NK Patients NCT05552261	Dompé Farmaceutici S.p.A	—
Active Not Recruiting	DOMPE -MT Neurotrophic Keratitis NCT06947850	Toyos Clinic	Phase 4
Unknown	An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With L NCT05566717	Medical Center Ophthalmology Associates	—
Withdrawn	Topical Insulin Drops for the Treatment of Neurotrophic Keratopathy. NCT05321251	University of Alberta	Phase 2 / Phase 3
Completed	Corneal Nerves After Treatment With Cenegermin NCT04627571	University of California, Los Angeles	—
Completed	Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjec NCT04909450	Claris Biotherapeutics, Inc.	Phase 1 / Phase 2
Completed	Nerve Growth Factor for the Treatment of Cornea Disease NCT04552730	Stanford University	—
Completed	REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients NCT04276558	RECORDATI GROUP	Phase 2
Recruiting	OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate NCT04573647	Sight Medical Doctors PLLC	—
Completed	Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis NCT04485546	Dompé Farmaceutici S.p.A	Phase 4
Completed	Topical Insulin - Utility and Results in Neurotrophic Keratopathy in Stages 2 and 3 NCT04820010	Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.	—
Terminated	Corneal Neurotization as a Treatment for Neurotrophic Keratopathy NCT05809245	Stanford University	N/A
Withdrawn	Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) Eye-drops in the Treatment of Neurotrophic NCT02707120	Biotechnology Institute IMASD	Phase 4
Terminated	Miniinvasive Corneal Neurotization. A Pilot Study. NCT03037450	University Hospital, Strasbourg, France	N/A
Completed	Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK NCT02227147	Dompé Farmaceutici S.p.A	Phase 2
Completed	Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis. NCT01756456	Dompé Farmaceutici S.p.A	Phase 1 / Phase 2